Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Rev+Esp+Quimioter 2021 ; 34 (2): 136-140 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Real-life use of remdesivir in hospitalized patients with COVID-19 #MMPMID33675220
Garcia-Vidal C; Meira F; Cozar-Llisto A; Duenas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Aguero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; Garcia F; Mensa J; Martinez JA; Sanjuan G; Soriano A
Rev Esp Quimioter 2021[Apr]; 34 (2): 136-140 PMID33675220show ga
OBJECTIVE: Controversial results on remdesivir efficacy have been reported. We aimed to report our real-life experience with the use of remdesivir from its availability in Spain. METHODS: We performed a descriptive study of all patients admitted for >/=48 hours with confirmed COVID-19 who received remdesivir between the 1st of July and the 30th of September 2020. RESULTS: A total of 123 patients out of 242 admitted with COVID-19 at our hospital (50.8%) received remdesivir. Median age was 58 years, 61% were males and 56.9 % received at least one anti-inflammatory treatment. No adverse events requiring remdesivir discontinuation were reported. The need of intensive care unit admission, mechanical ventilation and 30-days mortality were 19.5%, 7.3% and 4.1%, respectively. CONCLUSIONS: In our real-life experience, the use of remdesivir in hospitalized patients with COVID-19 was associated with a low mortality rate and good safety profile.
free
free
free
Rev+Esp+Quimioter 2021 ; 34 (2): 136-140
